H. Grosch

Dosimetric comparison of advanced radiotherapy approaches using photon techniques and particle therapy in the postoperative management of thymoma

L. Uhlmann, K. Herfarth, J. Debus, 2018, Acta oncologica.

[Thymus cancers: A clinical observation].

C. Weis, H. Hoffmann, M. Thomas, 2016, Der Pathologe.

Early Development of Ubiquitous Acanthocytosis and Extravascular Hemolysis in Lung Cancer Patients Receiving Alectinib

Michael Thomas, M. Hundemer, K. Kriegsmann, 2022, Cancers.

A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-line Treatment for EGFR-mutation Positive NSCLC Patients.

C. Schumann, N. Girard, G. Scagliotti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib.

G. Bepler, E. Smit, Keunchil Park, 2022, Clinical lung cancer.

Deficient CD247 expression is a typical histopathological characteristic of thymomas with cortical features

A. Marx, Michael Thomas, T. Muley, 2018, Histopathology.

A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY+E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx+) metastatic NSCLC.

G. Bepler, E. Smit, Keunchil Park, 2016 .